SYNG Pharmaceuticals Announces Issuance of Its Canadian Patent for Non-Hormonal Therapy for Endometriosis
SYNG Pharmaceuticals Inc. (SYNG), a Kingston, Ontario based women’s health biotech, is pleased to announce that on October 04, 2022, the Canadian Intellectual Property Office granted Canada Patent No. 2,903,608 titled, "Treatment of endometriosis, angiogenesis and/or endometrial lesion growth." - October 09, 2022
Press Releases 1 - 1 of 1